Navigation Links
CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
Date:6/16/2009

pent on the development of these expensive validations.

About IVT:

The Institute of Validation Technology (IVT) Conference Division features the most-notable validation and compliance experts in the FDA regulated industry. IVT stands alone in its quest to continually educate pharmaceutical, biopharmaceutical and medical device professionals in validation concepts from A-Z, AND global GXP regulatory initiatives. Through over 15 years of providing timely, cutting-edge conferences, IVT's philosophy remains that: "each of our events provides valuable take-home knowledge that can be immediately implemented at every level."

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is currently being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereo
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
3. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
4. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
5. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
6. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
7. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
10. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
11. Scientists advance safety of nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Eric Jimenez and ... Me , a revolutionary makeup application device. Designed to ... proven innovation in the palm of women’s hands to ... secret to Color Me’s success lies in its patented ... a rate of 15,000 pulses per minute, the device ...
(Date:9/2/2014)... NJ (PRWEB) September 02, 2014 BESLER ... protection services for hospitals, is pleased to announce that ... in-depth review of the FY 2015 Hospital Inpatient ... the Centers for Medicare & Medicaid Services. , “Hospitals ... variety of reasons,” said Jonathan Besler, BESLER’s President and ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the world-famous ... Lee has the unique distinction of being the first and ... history, Misty Lee is the first female magician to hold ... staff Medium at the Magic Castle,” says Misty Lee. “Even ... being at the Magic Castle, I can fascinate guests in ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
Breaking Medicine News(10 mins):Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5
... who fear their own death say they are more prepared ... whom further medical treatment is considered futile,// reveals research published ... Archives of Disease in Childhood. ,The findings ... in the care of sick newborns (neonatologists) across Australia and ...
... low numbers of organ donors in Australia is an ongoing ... ,In the latest edition of the Medical Journal ... of the issues surrounding organ donation in Australia. ... the second the impact of public education campaigns on organ ...
... According to a latest Government data, there is an alarming ... this could be linked to the plummeting sale of// antidepressants. ... and Prevention (CDC) also indicated that youth in their late ... Food and Drug Administration had issued a black box warning ...
... using a sophisticated form of analysis called meta-analysis, in which ... for// possibly preventing up to half of the cases of ... in the United States. The work was conducted by a ... Center at University of California, San Diego (UCSD), and colleagues ...
... the United States and a growing epidemic worldwide. Now, ... able to make a valuable contribution to an overall ... ,A study published in the Journal of Vertebral ... when used as part of an integrative treatment in ...
... there is a pronounced increase of mental illnesses ... spectrum disorders, obsessive// compulsive disorders and hyperkinetic illnesses. ... Pediatric and Adolescent Medicine. ,Researches are ... to the increased awareness about these diseases or ...
Cached Medicine News:Health News:Doctors’ Own Fear of Death Linked to Hastening Death of Very Sick Newborn 2Health News:The Search for Organ Donors 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Research Explores Chiropractic's Effect on Diabetes 2
(Date:9/2/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ( ... 2014 at 9:10 a.m. EDT , Aegis Capital ...
(Date:9/2/2014)... AVIV, Israel , September 2, 2014 ... "Company") (TASE, NASDAQ: EMITF ) announced today ... Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a ... 85% on a fully diluted basis, announced that on ... Medical holds approximately 30.8% of the voting power ("Gamida ...
(Date:9/2/2014)... N.J. , Sept. 2, 2014 /PRNewswire/ ... Company), a clinical stage biopharmaceutical company focused ... diseases where there remains an unmet medical ... vaccines and therapeutics, announced today promising preliminary ... ricin toxin vaccine RiVax™, in a non-human ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 2Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 3Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 4Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 5Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 6Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 7Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine 8
... NEW YORK, Jan. 13, 2011 Although 2010 brought ... healthcare reform repeal.  Investors should likely expect some volatility ... wreak havoc on healthcare reform, either through a repeal ... according to analysts at Standard & Poor,s Equity Research. ...
... N.J., Jan. 13, 2011 Quest Diagnostics Incorporated (NYSE: ... information and services, announced today that it will report fourth ... for 2011 on Tuesday, January 25, before the market opens. ... discuss the results beginning at 8:30 a.m. ET on that ...
Cached Medicine Technology:S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: